Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 entities : Teva pharmaceutical industries ltd save search
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Regeneron Pharmaceuticals, Inc. and Sanofi announced that a Phase 3 trial asses...
Published: 2022-07-14 (Crawled : 07:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results sanofi phase 3
Dupixent® (dupilumab) Phase 3 Trial Shows Positive Results in Children 1 to 11 Years of Age with Eosinophilic Esophagitis
Published: 2022-07-14 (Crawled : 06:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.46%
H: 0.09%
C: 0.09%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.0%
H: 1.64%
C: 0.48%
dupixent children trial positive results phase 3
Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol
Published: 2022-05-21 (Crawled : 12:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
evkeeza children cholesterol trial phase 3 rare
Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis
Published: 2022-03-26 (Crawled : 16:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent phase 3
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
dupixent urticaria phase 3 hiv
Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Published: 2022-02-18 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program
Published: 2022-02-18 (Crawled : 07:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -6.31%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.47%
H: 0.77%
C: -0.23%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.78%
H: 1.76%
C: -1.08%
dupixent ongoing program phase 3 urticaria
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
Published: 2022-01-19 (Crawled : 07:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -1.41%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 1.84%
H: 1.79%
C: 0.18%
dupixent trial positive phase 3
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Published: 2021-12-08 (Crawled : 23:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.85%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: -0.62%
H: 2.7%
C: 2.42%
dupixent positive results children phase 3
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Published: 2021-11-08 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 3.88%
H: 0.78%
C: 0.68%
covid casirivimab phase 3
Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease
Published: 2021-10-25 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.02%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.89%
H: 0.26%
C: -0.12%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.38%
H: 0.88%
C: 0.44%
disease phase 3 trial dupixent
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Published: 2021-10-22 (Crawled : 09:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: 0.0%
disease phase 3 skin trial dupixent
New England Journal of Medicine Publishes Positive Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Treat COVID-19
Published: 2021-09-29 (Crawled : 21:00) - prnewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.02%
H: 0.2%
C: -0.31%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.17%
H: 0.96%
C: -0.42%
covid positive results casirivimab phase 3 trial trial results
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.